Thymalfasin is under clinical development by SciClone Pharmaceuticals and currently in Phase II for Cystic Fibrosis. According to GlobalData, Phase II drugs for Cystic Fibrosis have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Thymalfasin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Thymalfasin overview
Thymalfasin (Zadaxin) is a synthetic polypeptide consisting of 28 amino acids, a synthetic version of thymosin alpha 1, a substance found naturally in the circulation and produced in the body's thymus gland. It is formulated as an injection for the sub-cutaneous route of administration. It is used different indications such as chronic Hepatitis B, cancer adjuvant, vaccine enhancer and immunostimulant. It is used as an adjuvant for influenza vaccination in immunocompromised individuals.
Thymalfasin is under development for the treatment of solid tumor, thymoma, thymic carcinoma. It was also under development for the treatment of advanced stage metastatic malignant melanoma (US) and non-small cell lung cancer, sepsis and pneumonia.
SciClone Pharmaceuticals overview
SciClone Pharmaceuticals (SciClone) is a specialty pharmaceutical company that focuses on the development, in-licensing, and commercialization of pharmaceutical products. The company’s pipeline products include ORSERDU (elacestrant) for the treatment of postmenopausal women or adult men; Vaborem (Meropenem+Vaborbactam) for adults with complicated urinary tract infections; Vibativ (telavancin) treats hospital-acquired and ventilator- associated bacterial pneumonia; RRx-001 treats solid tumors; Omburtamab treats central nervous system (CNS) and others. Its therapeutic areas include oncology, infectious diseases, and cardiovascular disorders. The company collaborates with pharmaceutical partners to market multiple branded products. SciClone is headquartered in Shanghai, China.
For a complete picture of Thymalfasin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
